Bond.az White LogoBond.az Black Logo
→
EN ▾
AZENRU
Gold continues to fall in global marketsUS Strikes Expand in Iran: 'Rain of Fire'Glenn Close and Ridley Scott to Receive Honorary OscarsNetanyahu to run again in upcoming electionsRussian court confirms sentence for Armenian bloggerIncentives in the Great Return programRussian ambassador returns to YerevanTrump: Erdoğan is my very good friendIAEA adopts resolution against IranAraz Nasirov leaves his post at TABIBGold continues to fall in global marketsUS Strikes Expand in Iran: 'Rain of Fire'Glenn Close and Ridley Scott to Receive Honorary OscarsNetanyahu to run again in upcoming electionsRussian court confirms sentence for Armenian bloggerIncentives in the Great Return programRussian ambassador returns to YerevanTrump: Erdoğan is my very good friendIAEA adopts resolution against IranAraz Nasirov leaves his post at TABIB
Personalize
Bond.az White LogoBond.az Black Logo
AZENRU

#hypochondroplasia

Latest news and interesting information about hypochondroplasia.

BioMarin Neutral Rating, $50 Target by HC Wainwright
2026-05-22 11:53
|
473

BioMarin Neutral Rating, $50 Target by HC Wainwright

H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.

ANALYST RATINGS →
0
BioMarin stock surges on positive hypochondroplasia trial data
2026-05-20 20:44
|
462

BioMarin stock surges on positive hypochondroplasia trial data

BioMarin stock jumped 4.8% after positive Phase 3 trial results for VOXZOGO in hypochondroplasia, showing significant growth improvements.

STOCK MARKETS →
0
...